Cargando…

The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study

BACKGROUND: Previous studies have indicated that vitamin K deficiency is common in non-bleeding critically ill patients with slightly prolonged prothrombin time-international normalized ratio (PT-INR). It has never been investigated thoroughly whether the administration of vitamin K to these patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahlberg, Sofia, Schött, Ulf, Kander, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814614/
https://www.ncbi.nlm.nih.gov/pubmed/33461606
http://dx.doi.org/10.1186/s40560-020-00517-5
_version_ 1783638089008152576
author Dahlberg, Sofia
Schött, Ulf
Kander, Thomas
author_facet Dahlberg, Sofia
Schött, Ulf
Kander, Thomas
author_sort Dahlberg, Sofia
collection PubMed
description BACKGROUND: Previous studies have indicated that vitamin K deficiency is common in non-bleeding critically ill patients with slightly prolonged prothrombin time-international normalized ratio (PT-INR). It has never been investigated thoroughly whether the administration of vitamin K to these patients could affect their PT-INR. Therefore, the aim of this registry study was to evaluate changes in PT-INR in response to vitamin K in critically ill patients with PT-INR in the range of 1.3–1.9. METHODS: Patients admitted to a mixed 9-bed general intensive care unit at a University Hospital, between 2013 and 2019 (n = 4541) with a PT-INR between 1.3 and 1.9 at any time during the stay were identified. Patients who received vitamin K with appropriate sampling times for PT-INR and without exclusion criteria were matched with propensity score to patients from the same cohort who did not receive vitamin K (controls). PT-INR was measured at admission, within 12 h before vitamin K administration and 12–36 h following vitamin K administration. Exclusion criteria included pre-existing liver cirrhosis, any plasma or platelet transfusion, or > 1 unit red blood cell transfusion between PT-INR samplings. RESULTS: Propensity score matching resulted in two groups of patients with 129 patients in each group. PT-INR decreased in both groups (1.4 [1.3–1.4] in the vitamin K group and 1.4 [1.3–1.6] in the controls, p < 0.001 and p = 0.004, respectively). The decrease in PT-INR was slightly more pronounced in patients who received vitamin K (delta PT-INR − 0.10 [− 0.30 to − 0.10] in the vitamin K group and − 0.10 [− 0.20 to 0.10] in the controls, p = 0.01). CONCLUSION: In critically ill patients with a PT-INR of 1.3–1.9, the administration of vitamin K resulted in a slightly larger decrease of PT-INR 12–36 h after administration compared to controls. Future studies should focus on identifying which patient populations may benefit most from vitamin K administration as well as whether vitamin K could be a better alternative than plasma or prothrombin complex concentrate to improve PT-INR before non-emergent invasive procedures.
format Online
Article
Text
id pubmed-7814614
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78146142021-01-26 The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study Dahlberg, Sofia Schött, Ulf Kander, Thomas J Intensive Care Research BACKGROUND: Previous studies have indicated that vitamin K deficiency is common in non-bleeding critically ill patients with slightly prolonged prothrombin time-international normalized ratio (PT-INR). It has never been investigated thoroughly whether the administration of vitamin K to these patients could affect their PT-INR. Therefore, the aim of this registry study was to evaluate changes in PT-INR in response to vitamin K in critically ill patients with PT-INR in the range of 1.3–1.9. METHODS: Patients admitted to a mixed 9-bed general intensive care unit at a University Hospital, between 2013 and 2019 (n = 4541) with a PT-INR between 1.3 and 1.9 at any time during the stay were identified. Patients who received vitamin K with appropriate sampling times for PT-INR and without exclusion criteria were matched with propensity score to patients from the same cohort who did not receive vitamin K (controls). PT-INR was measured at admission, within 12 h before vitamin K administration and 12–36 h following vitamin K administration. Exclusion criteria included pre-existing liver cirrhosis, any plasma or platelet transfusion, or > 1 unit red blood cell transfusion between PT-INR samplings. RESULTS: Propensity score matching resulted in two groups of patients with 129 patients in each group. PT-INR decreased in both groups (1.4 [1.3–1.4] in the vitamin K group and 1.4 [1.3–1.6] in the controls, p < 0.001 and p = 0.004, respectively). The decrease in PT-INR was slightly more pronounced in patients who received vitamin K (delta PT-INR − 0.10 [− 0.30 to − 0.10] in the vitamin K group and − 0.10 [− 0.20 to 0.10] in the controls, p = 0.01). CONCLUSION: In critically ill patients with a PT-INR of 1.3–1.9, the administration of vitamin K resulted in a slightly larger decrease of PT-INR 12–36 h after administration compared to controls. Future studies should focus on identifying which patient populations may benefit most from vitamin K administration as well as whether vitamin K could be a better alternative than plasma or prothrombin complex concentrate to improve PT-INR before non-emergent invasive procedures. BioMed Central 2021-01-18 /pmc/articles/PMC7814614/ /pubmed/33461606 http://dx.doi.org/10.1186/s40560-020-00517-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Dahlberg, Sofia
Schött, Ulf
Kander, Thomas
The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study
title The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study
title_full The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study
title_fullStr The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study
title_full_unstemmed The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study
title_short The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study
title_sort effect of vitamin k on prothrombin time in critically ill patients: an observational registry study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814614/
https://www.ncbi.nlm.nih.gov/pubmed/33461606
http://dx.doi.org/10.1186/s40560-020-00517-5
work_keys_str_mv AT dahlbergsofia theeffectofvitaminkonprothrombintimeincriticallyillpatientsanobservationalregistrystudy
AT schottulf theeffectofvitaminkonprothrombintimeincriticallyillpatientsanobservationalregistrystudy
AT kanderthomas theeffectofvitaminkonprothrombintimeincriticallyillpatientsanobservationalregistrystudy
AT dahlbergsofia effectofvitaminkonprothrombintimeincriticallyillpatientsanobservationalregistrystudy
AT schottulf effectofvitaminkonprothrombintimeincriticallyillpatientsanobservationalregistrystudy
AT kanderthomas effectofvitaminkonprothrombintimeincriticallyillpatientsanobservationalregistrystudy